ID   U-HO1
AC   CVCL_2220
SY   U-H01; UHO1
DR   BioSample; SAMN03473507
DR   cancercelllines; CVCL_2220
DR   Cell_Model_Passport; SIDM01831
DR   Cosmic; 1289702
DR   Cosmic; 1432042
DR   DepMap; ACH-001685
DR   DSMZ; ACC-626
DR   DSMZCellDive; ACC-626
DR   GEO; GSM381299
DR   IGRhCellID; U-HO1
DR   Progenetix; CVCL_2220
DR   Wikidata; Q54973621
RX   CelloPub=CLPUB00457;
RX   PubMed=18253030;
RX   PubMed=18820924;
RX   PubMed=19380639;
RX   PubMed=21144060;
RX   PubMed=29533902;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: ~4 days (PubMed=18253030); ~100 hours (DSMZ=ACC-626).
CC   Sequence variation: Mutation; HGNC; 9642; PTPN1; Unexplicit; Ex2-8del; Zygosity=Unspecified (CelloPub=CLPUB00457).
CC   Sequence variation: Gene deletion; HGNC; 11896; TNFAIP3; Zygosity=Heterozygous (PubMed=19380639).
CC   Sequence variation: Mutation; HGNC; 11896; TNFAIP3; Simple; p.Met43fs (c.127-134del) (del 193-200); Zygosity=Heterozygous (PubMed=19380639).
CC   Omics: SNP array analysis.
CC   Anecdotal: Andreas Mader, the first author of the paper (PubMed=18253030) describing this cell line is the patient that donated the cell line. As it is not frequent to see a patient 'acknowledged' by being an author this fact should be emphasized.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DepMap=ACH-001685; DSMZ=ACC-626
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 11,12
ST   D16S539: 11,13
ST   D18S51: 14
ST   D19S433: 13,14
ST   D21S11: 30,32.2
ST   D2S1338: 23,24
ST   D3S1358: 13,17
ST   D5S818: 11
ST   D7S820: 8,10
ST   D8S1179: 13,16
ST   FGA: 21,24
ST   Penta D: 9,13
ST   Penta E: 5,18
ST   TH01: 7,9.3
ST   TPOX: 8,10
ST   vWA: 18
DI   NCIt; C9357; Hodgkin lymphoma
DI   ORDO; Orphanet_98293; Hodgkin lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   23Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 29
//
RX   CelloPub=CLPUB00457;
RA   Wegener S., Mader A., Melzner I., Bruderlein S., Moller P.;
RT   "Lack of PTPN1 (PTP1B) in U-HO1, a new Hodgkin-derived cell line,
RT   protects cells from apoptosis.";
RL   Haematologica 92 Suppl. 5:39-39(2007).
//
RX   PubMed=18253030; DOI=10.1159/000112062;
RA   Mader A., Bruderlein S., Wegener S., Melzner I., Popov S.W.,
RA   Muller-Hermelink H.-K., Barth T.F.E., Viardot A., Moller P.;
RT   "U-HO1, a new cell line derived from a primary refractory classical
RT   Hodgkin lymphoma.";
RL   Cytogenet. Genome Res. 119:204-210(2007).
//
RX   PubMed=18820924; DOI=10.1007/s00292-008-1055-6;
RA   Moller P., Mader A., Barth T.F.E., Bruderlein S.;
RT   "U-HO1. A new cell line derived from a primary refractory classical
RT   Hodgkin lymphoma.";
RL   Pathologe 29:317-318(2008).
//
RX   PubMed=19380639; DOI=10.1084/jem.20090528;
RA   Schmitz R., Hansmann M.-L., Bohle V., Martin-Subero J.I., Hartmann S.,
RA   Mechtersheimer G., Klapper W., Vater I., Giefing M., Gesk S.,
RA   Stanelle J., Siebert R., Kuppers R.;
RT   "TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and
RT   primary mediastinal B cell lymphoma.";
RL   J. Exp. Med. 206:981-989(2009).
//
RX   PubMed=21144060; DOI=10.1186/1471-2121-11-99;
RA   Knecht H., Bruderlein S., Wegener S., Lichtensztejn D.,
RA   Lichtensztejn Z., Lemieux B., Moller P., Mai S.;
RT   "3D nuclear organization of telomeres in the Hodgkin cell lines U-HO1
RT   and U-HO1-PTPN1: PTPN1 expression prevents the formation of very short
RT   telomeres including 't-stumps'.";
RL   BMC Cell Biol. 11:99.1-99.10(2010).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//